Bush Odonnell Investment Advisors Inc. Holds Stake in Merck & Company, Inc. (MRK)

Bush Odonnell Investment Advisors Inc. continued to hold its position in Merck & Company, Inc. (NYSE:MRK) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,560 shares of the company’s stock at the end of the 2nd quarter. Bush Odonnell Investment Advisors Inc.’s holdings in Merck & were worth $549,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stelac Advisory Services LLC acquired a new stake in shares of Merck & in the 2nd quarter worth approximately $104,000. Perennial Advisors LLC grew its holdings in Merck & by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after buying an additional 157 shares during the last quarter. Cascade Investment Advisors Inc. grew its holdings in Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after buying an additional 232 shares during the last quarter. Vigilant Capital Management LLC grew its holdings in Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after buying an additional 250 shares during the last quarter. Finally, Solaris Asset Management LLC grew its holdings in Merck & by 6.3% during the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after buying an additional 115 shares during the last quarter. Institutional investors and hedge funds own 73.15% of the company’s stock.

In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.25% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.themarketsdaily.com/2017/11/15/bush-odonnell-investment-advisors-inc-holds-stake-in-merck-company-inc-mrk.html.

Merck & Company, Inc. (NYSE MRK) opened at $54.99 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. The firm has a market capitalization of $150,116.47, a price-to-earnings ratio of 14.16, a P/E/G ratio of 2.37 and a beta of 0.78. Merck & Company, Inc. has a 52-week low of $54.41 and a 52-week high of $66.80.

Merck & (NYSE:MRK) last issued its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. The business had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period last year, the company posted $1.07 EPS. analysts predict that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

A number of equities research analysts have commented on MRK shares. BidaskClub cut Merck & from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. BMO Capital Markets reiterated an “outperform” rating and set a $73.00 target price (down previously from $74.00) on shares of Merck & in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $74.00 target price (up previously from $70.00) on shares of Merck & in a report on Thursday, July 27th. Piper Jaffray Companies set a $70.00 target price on Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. Finally, UBS AG increased their target price on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $67.07.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply